Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center in cardiology) with data of other hospitals.Mat...
Saved in:
| Main Authors: | N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. V. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2021-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness
by: N. Yu. Mironov, et al.
Published: (2021-05-01) -
FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW
by: S. A. Zenin, et al.
Published: (2015-09-01) -
Clinical and pathogenetic characteristics and management of patients with atrial fibrillation in a cardiology department at the present time
by: V. K. Kurashin, et al.
Published: (2020-07-01) -
Propafenone efficacy and safety in restoring and maintaining sinus rhythm in patients with recurrent atrial fibrillation: results of the open, prospective placebo-controlled trial
by: I. G. Fomina, et al.
Published: (2005-04-01) -
Robotic-enhanced hybrid ablation for persistent and long-standing atrial fibrillation: Early assessment of feasibility, safety, and efficacyCentral MessagePerspective
by: Stefano Schena, MD, PhD, et al.
Published: (2024-06-01)